Cosyntropin Research: What 47,635 Studies Show (2026) | RetatrutideCompare

Cosyntropin — 47,635 studies indexed on PubMed. Synthetic ACTH analog used diagnostically for adrenal stimulation testing. Half-life: ~15 minutes. FDA status: FDA-approved.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Cosyntropin?

There are approximately 47,635 studies indexed on PubMed that mention Cosyntropin (Cortrosyn, Tetracosactide), based on a search last updated 2026-06-18.

Is Cosyntropin FDA-approved?

FDA status: FDA-approved.

How does Cosyntropin work?

Synthetic ACTH analog used diagnostically for adrenal stimulation testing.

Reference facts

Also known as: Cortrosyn, Tetracosactide, ACTH (1-24)
Category: Hormonal & Pituitary
Mechanism of action: Synthetic ACTH analog used diagnostically for adrenal stimulation testing.
Targets: MC2R
Indications under research or approved: Diagnosis of adrenal insufficiency
Regulatory status (reference entry): FDA-approved
Half-life: ~15 minutes
Sequence: SYSMEHFRWGKPVGKKRRPVKVYP
Sequence notes: 24-residue N-terminal fragment of ACTH containing the full bioactivity in a less immunogenic molecule.
Molecular weight (Da): 2933
First reported: 1965

Primary References

Cortrosyn FDA label

Explore research articles about Cosyntropin

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.